Stockreport

Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

UROVANT SCIENCES LTD COMMON  (UROV) 
Last urovant sciences ltd common earnings: 2/13 04:15 pm Check Earnings Report
PDF Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturition [Read more]